Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 30

Sanofi’s Nexviazyme Shows Positive Phase 3 Results in Infantile Pompe Diseas

Jul 2, 2026
Sanofi has reported positive Phase 3 results for Nexviazyme, also known as avalglucosidase alfa, in infants with infantile-onset Pompe disease, a rare and life-threatening genetic…
Read More...

FDA Expands CASGEVY Approval for Children With Blood Disorders

Jul 1, 2026
Vertex Pharmaceuticals has received expanded approval from the U.S. Food and Drug Administration for CASGEVY® (exagamglogene autotemcel), allowing the gene-editing therapy to be used in…
Read More...

Innovent, Lilly Expand Verzenios Access for Breast Cancer in China

Jul 1, 2026
Innovent Biologics and Eli Lilly and Company have entered into a new distribution and promotion agreement for Verzenios® (abemaciclib) in mainland China, expanding their commercial…
Read More...

Zymeworks to Acquire Theravance Biopharma in $929 Million Deal

Jun 30, 2026
Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. in an all-cash transaction valued at approximately $929 million, marking a significant consolidation in the biotechnology…
Read More...

EMA Panel Backs Lilly’s Jaypirca for Chronic Lymphocytic Leukemia

Jun 30, 2026
Eli Lilly and Company has moved a step closer to expanding the use of its blood cancer therapy Jaypirca (pirtobrutinib) in Europe after receiving a positive opinion from the European…
Read More...

Talawar Therapeutics Announces $285 Million Nasdaq Merger Deal

Jun 30, 2026
Talawar Tx Inc., a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammatory diseases, has signed a definitive business combination…
Read More...

AstraZeneca, YMCA Launch National Cancer Education Partnership

Jun 26, 2026
AstraZeneca and YMCA of the USA (Y-USA) have launched a five-year, multimillion-dollar partnership aimed at improving cancer awareness, increasing screening and early detection rates,…
Read More...

Antares, Novartis Partner on Cancer Drug Discovery

Jun 26, 2026
Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop, and commercialize a new generation of small-molecule cancer therapies targeting…
Read More...

FDA Approves TRYNGOLZA for Severe Hypertriglyceridemia

Jun 26, 2026
Ionis Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZA (olezarsen), a first-of-its-kind therapy designed to reduce triglyceride levels and…
Read More...

RQ Bio Raises $115 Million for Influenza Antibody Therapy

Jun 26, 2026
RQ Bio has secured $115 million (£85.5 million) in an oversubscribed Series A financing, providing the biotechnology company with significant resources to advance the clinical…
Read More...
Previous 1 … 28 29 30 31 32 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.